VistaGen Therapeutics (VTGN) Receives Daily News Sentiment Rating of 0.13

Media headlines about VistaGen Therapeutics (NASDAQ:VTGN) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. VistaGen Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.6018891210111 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of VistaGen Therapeutics (VTGN) opened at $0.92 on Wednesday. The company has a debt-to-equity ratio of -0.01, a current ratio of 1.23 and a quick ratio of 1.23. VistaGen Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.92.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). sell-side analysts forecast that VistaGen Therapeutics will post -1.99 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/06/vistagen-therapeutics-vtgn-receives-daily-news-sentiment-rating-of-0-13.html.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

Insider Buying and Selling by Quarter for VistaGen Therapeutics (NASDAQ:VTGN)

What are top analysts saying about VistaGen Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for VistaGen Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit